Bills/H.R. 5139

EPIPEN Act

EPIPEN Act

In CommitteeHealthcareHouseHouse Bill · 119th Congress
Bill Progress · House
Introduced
Committee
Passed House
Passed Senate
Passed Both
Signed

Plain Language Summary

# EPIPEN Act (HR 5139) - Summary **What the Bill Would Do:** The EPIPEN Act is a proposed law currently under consideration in Congress that aims to address issues related to EpiPen availability and affordability. EpiPens are emergency auto-injectors containing epinephrine, used to treat severe allergic reactions. While the bill's specific provisions aren't detailed in the information provided, bills with this title typically focus on measures like increasing access to these life-saving devices, controlling costs, or improving their availability in schools and public places. **Who It Affects:** This legislation would primarily impact people with severe allergies, families managing allergic conditions, schools and public institutions that stock emergency medications, and potentially the pharmaceutical companies that manufacture EpiPens.

Healthcare providers and insurance companies could also be affected depending on the bill's final provisions. **Current Status:** The bill is currently in committee, meaning it's in early stages of review and has not yet been debated or voted on by the full House of Representatives. Many bills at this stage do not advance further in the legislative process. *Note: Without access to the full bill text, this summary reflects typical provisions of legislation addressing EpiPen accessibility. For specific details about what this bill proposes, consult Congress.gov.*.

Advertisement

Latest Action

September 4, 2025

Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Sponsor

1 cosponsor

Key Dates

Introduced
September 4, 2025
Last Updated
September 4, 2025
Read Full Text on Congress.gov →
Advertisement